Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ict > winter 2020 > race for children act: product development considerations

PUBLICATIONS

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

News and Press Releases

Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer

Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 - iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-289 in the ESMO journal Immuno-Oncology and Technology (IOTECH).
More info >>

All releases >>